These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25370705)

  • 1. Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma.
    Artzi M; Blumenthal DT; Bokstein F; Nadav G; Liberman G; Aizenstein O; Ben Bashat D
    J Neurooncol; 2015 Jan; 121(2):349-57. PubMed ID: 25370705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma.
    Liberman G; Louzoun Y; Aizenstein O; Blumenthal DT; Bokstein F; Palmon M; Corn BW; Ben Bashat D
    Eur J Radiol; 2013 Feb; 82(2):e87-94. PubMed ID: 23017192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.
    Artzi M; Liberman G; Nadav G; Blumenthal DT; Bokstein F; Aizenstein O; Ben Bashat D
    J Neurooncol; 2016 May; 127(3):515-24. PubMed ID: 26754857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
    Hsu YH; Ferl GZ; Ng CM
    Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J; Pachinger C; Pelz M; Kleiser R
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
    Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
    Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On differentiation between vasogenic edema and non-enhancing tumor in high-grade glioma patients using a support vector machine classifier based upon pre and post-surgery MRI images.
    Sengupta A; Agarwal S; Gupta PK; Ahlawat S; Patir R; Gupta RK; Singh A
    Eur J Radiol; 2018 Sep; 106():199-208. PubMed ID: 30150045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
    Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
    Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
    J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.
    Leu K; Enzmann DR; Woodworth DC; Harris RJ; Tran AN; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    Cancer Imaging; 2014 Nov; 14(1):31. PubMed ID: 25608485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.
    Port RE; Bernstein LJ; Barboriak DP; Xu L; Roberts TP; van Bruggen N
    Magn Reson Med; 2010 Aug; 64(2):408-17. PubMed ID: 20665785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.
    Piludu F; Marzi S; Pace A; Villani V; Fabi A; Carapella CM; Terrenato I; Antenucci A; Vidiri A
    Neuroradiology; 2015 Dec; 57(12):1269-80. PubMed ID: 26364181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cerebral blood volume measurements using dynamic contrast enhancement in comparison to dynamic susceptibility contrast MRI.
    Artzi M; Liberman G; Nadav G; Vitinshtein F; Blumenthal DT; Bokstein F; Aizenstein O; Ben Bashat D
    Neuroradiology; 2015 Jul; 57(7):671-8. PubMed ID: 25845809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.
    Takano S; Kimu H; Tsuda K; Osuka S; Nakai K; Yamamoto T; Ishikawa E; Akutsu H; Matsuda M; Matsumura A
    Acta Neurochir Suppl; 2013; 118():185-9. PubMed ID: 23564129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of Radiomics features of Peritumoral Vasogenic Edema extracted from fluid-attenuated inversion recovery images in glioblastoma and isolated brain metastasis, using T1-dynamic contrast-enhanced Perfusion analysis.
    Parvaze PS; Bhattacharjee R; Verma YK; Singh RK; Yadav V; Singh A; Khanna G; Ahlawat S; Trivedi R; Patir R; Vaishya S; Shah TJ; Gupta RK
    NMR Biomed; 2023 May; 36(5):e4884. PubMed ID: 36453877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
    Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
    Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.